JP2023537316A5 - - Google Patents

Info

Publication number
JP2023537316A5
JP2023537316A5 JP2023506315A JP2023506315A JP2023537316A5 JP 2023537316 A5 JP2023537316 A5 JP 2023537316A5 JP 2023506315 A JP2023506315 A JP 2023506315A JP 2023506315 A JP2023506315 A JP 2023506315A JP 2023537316 A5 JP2023537316 A5 JP 2023537316A5
Authority
JP
Japan
Prior art keywords
approximately
histidine
seq
pharmaceutical preparation
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023506315A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023537316A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/044043 external-priority patent/WO2022026914A1/en
Publication of JP2023537316A publication Critical patent/JP2023537316A/ja
Publication of JP2023537316A5 publication Critical patent/JP2023537316A5/ja
Pending legal-status Critical Current

Links

JP2023506315A 2020-07-31 2021-07-30 抗コネキシン抗体製剤 Pending JP2023537316A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063059502P 2020-07-31 2020-07-31
US63/059,502 2020-07-31
PCT/US2021/044043 WO2022026914A1 (en) 2020-07-31 2021-07-30 Anti-connexin antibody formulations

Publications (2)

Publication Number Publication Date
JP2023537316A JP2023537316A (ja) 2023-08-31
JP2023537316A5 true JP2023537316A5 (cg-RX-API-DMAC7.html) 2024-08-07

Family

ID=80002768

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023506315A Pending JP2023537316A (ja) 2020-07-31 2021-07-30 抗コネキシン抗体製剤

Country Status (9)

Country Link
US (2) US11912764B2 (cg-RX-API-DMAC7.html)
EP (1) EP4188544A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023537316A (cg-RX-API-DMAC7.html)
KR (1) KR20230042744A (cg-RX-API-DMAC7.html)
CN (1) CN116234576A (cg-RX-API-DMAC7.html)
AU (1) AU2021316119A1 (cg-RX-API-DMAC7.html)
CA (1) CA3190474A1 (cg-RX-API-DMAC7.html)
IL (1) IL300245A (cg-RX-API-DMAC7.html)
WO (1) WO2022026914A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116854816A (zh) * 2018-04-02 2023-10-10 阿拉玛布治疗学股份有限公司 连接蛋白43抗体及其用途
AU2020219112A1 (en) * 2019-02-04 2021-08-26 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof
IL300245A (en) 2020-07-31 2023-03-01 Alamab Therapeutics Inc Anti-connexin antibody formulations
US20250277017A1 (en) * 2022-04-29 2025-09-04 Board Of Regents, The University Of Texas System Compositions and methods for treating eye diseases
WO2025006774A1 (en) * 2023-06-30 2025-01-02 Alamab Therapeutics, Inc. Method of treating osteoarthritis
EP4761813A1 (en) * 2023-08-14 2026-06-24 Alamab Therapeutics, Inc. Method of treating stroke
WO2025245485A1 (en) * 2024-05-24 2025-11-27 Alamab Therapeutics, Inc. Method of treating bone cancers

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101573131B (zh) 2005-02-03 2017-12-01 科达治疗有限公司 抗‑连接蛋白化合物及其治疗应用
EP1865986B1 (en) * 2005-03-08 2016-02-17 Pfizer Products Inc. Anti-ctla-4 antibody compositions
WO2009148613A1 (en) 2008-06-04 2009-12-10 Coda Therapeutics, Inc. Treatment of pain with gap junction modulation compounds
CN102413839A (zh) * 2009-03-06 2012-04-11 医学免疫有限责任公司 人源化抗cd19抗体制剂
US8956868B2 (en) 2010-12-27 2015-02-17 Lsip, Llc Induced pluripotent stem cells produced with a connexin inhibitor and a TGF-β signaling inhibitor
WO2015027120A1 (en) 2013-08-21 2015-02-26 Jiang Jean X Compositions and methods for targeting connexin hemichannels
US9493552B2 (en) 2013-11-15 2016-11-15 China Synthetic Rubber Corporation Therapeutic biologic for treatment of hepatocellular carcinoma
WO2016029191A2 (en) 2014-08-22 2016-02-25 Auckland Uniservices Limited Channel modulators
EP3394099A4 (en) * 2015-12-22 2019-11-27 Merck Sharp & Dohme Corp. Formulations of Manipulated Anti- IL-10 Antibodies
BR112018017031A2 (pt) * 2016-02-23 2019-01-22 Sesen Bio Inc formulações de antagonista de il-6 e usos das mesmas
AU2017224122B2 (en) * 2016-02-26 2024-04-11 The Board Of Regents Of The University Of Texas System Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof
WO2017190152A1 (en) 2016-04-29 2017-11-02 Ocunexus Therapeutics, Inc. Sustained release drug delivery devices
JOP20170170B1 (ar) 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
TWI911431B (zh) * 2017-03-01 2026-01-11 英商梅迪繆思有限公司 抗rsv單株抗體配製物
US11603407B2 (en) * 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
MA49960A (fr) * 2017-08-25 2021-06-02 Omeros Corp Formulations d'anticorps inhibiteurs de masp-2 hautement concentrées à faible viscosité, kits et méthodes de traitement de sujets souffrant d'un syndrome hémolytique atypique
CN116854816A (zh) * 2018-04-02 2023-10-10 阿拉玛布治疗学股份有限公司 连接蛋白43抗体及其用途
MX2021005708A (es) * 2018-11-16 2021-09-21 Bristol Myers Squibb Co Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.
AU2020219112A1 (en) * 2019-02-04 2021-08-26 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof
CA3156812A1 (en) * 2019-10-02 2021-04-08 Alamab Therapeutics, Inc. Anti-connexin antibody formulations
IL300245A (en) 2020-07-31 2023-03-01 Alamab Therapeutics Inc Anti-connexin antibody formulations

Similar Documents

Publication Publication Date Title
JP2022552152A5 (cg-RX-API-DMAC7.html)
JP6836500B2 (ja) 自己免疫状態および炎症状態を治療するための方法および組成物
JP7593979B2 (ja) バイオフィルムの除去のためのペプチドおよび抗体
EP3380518B1 (en) Anti-complement factor c1q fab fragments and uses thereof
JP2025122007A (ja) Burkholderia感染の処置のための組成物および方法
JP7627255B2 (ja) バイオフィルムを破壊するための抗体組成物
ES2965283T3 (es) Tratamiento de pacientes con hemoglobinuria paroxística nocturna mediante un inhibidor del complemento
JP2021512881A5 (cg-RX-API-DMAC7.html)
EP2099489B1 (en) Compositions and methods for treating a neoplasm
ES2734886T3 (es) Anticuerpos anti-clusterina y fragmentos de unión a antígeno y su uso para reducir el volumen tumoral
ES2543095T3 (es) Agentes de unión a TLR3
JP2023517234A5 (cg-RX-API-DMAC7.html)
TW200900420A (en) Hepcidin, hepcidin antagonists and methods of use
EA028574B1 (ru) Способ лечения b-клеточных злокачественных новообразований, экспрессирующих cd19
UA129282C2 (uk) Спосіб лікування або профілактики пов'язаних з c5 хвороб
ES2994131T3 (en) Compositions and methods for treating cancer
JP2024506940A5 (cg-RX-API-DMAC7.html)
CN116585468A (zh) 血浆激肽释放酶结合蛋白和其在治疗遗传性血管性水肿中的用途
JP2022105056A (ja) 高濃度の抗vegf抗体を含有するタンパク質溶液製剤
TW202003046A (zh) 以鉑為主之劑與抗組織因子抗體-藥物共軛物的組合治療癌症之方法
ES2855973T3 (es) Nuevo anticuerpo útil en trastornos neurológicos o neurodegenerativos
EA200501131A1 (ru) Парентеральные композиции пептидов для лечения системной красной волчанки
JP2023553538A5 (cg-RX-API-DMAC7.html)
US20230242626A1 (en) Composition for treatment and prevention of covid-19
CN112533639A (zh) 掩蔽的抗体的药物配制品